A multiple sclerosis drug has been tested

Evobrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor lowering the risk of lesions in the brain. This is due to chronic CNS inflammation, active exacerbations and MRI findings. Phase II results evaluated the effect of evobrutinib therapy on lesion volume that slowly increased from baseline to 48 weeks.

According to scientists, evobrutinib exhibited a dose-dependent effect, while the dosage of 75 mg twice a day showed the best result. The candidate has shown an effect on the level of other biomarkers of the disease, considering as a promising way to assess the progression of MS. This means that the drug provided the decreased level of blood neurofilaments at the 12th week of treatment. At the 37th Congress of the European Committee, new data on the research and treatment of multiple sclerosis were presented a few days after the end of recruitment of participants in the III phase of the EVOLUTION RMS program, in which evobrutinib is being investigated.

Source: PharmaMedia